Class / Patent application number | Description | Number of patent applications / Date published |
514263370 | Nitrogen bonded directly to a ring carbon of the purine ring system (e.g., guanine, etc.) | 15 |
20080249115 | Non Peptide Agonists and Antagonists of Adrenomedullin and Gastric Releasing Peptide - This invention relates, e.g., to methods for inhibiting or stimulating an activity of an adrenomedullin (AM) or gastrin releasing peptide (GRP) peptide hormone, comprising contacting the peptide with a small molecule, non-peptide, modulatory agent of the invention. Complexes of these modulatory agents with other components, such as the peptides or blocking antibodies specific for the peptides, are also described, as are pharmaceutical compositions comprising the modulatory agents, and methods for using the modulatory agents to diagnose or treat patients. | 10-09-2008 |
20080287471 | 4'-Substituted Carbovir And Abacavir-Derivatives As Well As Related Compounds With Hiv And Hcv Antiviral Activity - The application relates to compounds with activity against infectious viruses. Accordingly, in one embodiment the invention provides a compound of the invention which is a compound of Formula I: (I) wherein: B is adenine, guanine cytosine, uracil, thymine, 7-deazaadenine, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deaza-8-azaadenine, inosine, nebularine, nitropyrrole, nitroindole, 2-aminopurine, 2-amino-6-chloropuriine, 2,6-diaminopurine, hypoxanthine, pseudouridine, pseudo-cytosine, pseudoisocytosine, 5-propynylcytosine, isocytosines, isoguanine, 7-deazaguanine, 2-thiopyrimidine, 6-thioguanine, 4-thiothymine, 4-thiouracil O | 11-20-2008 |
20090076038 | DEUTERIUM-ENRICHED ENTECAVIR - The present application describes deuterium-enriched entecavir, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-19-2009 |
20090149482 | STEREOCHEMICALLY DEFINED DIPEPTIDE ESTERS OF ANTIVIRAL AGENTS FOR ENHANCED OCULAR TREATMENT - Stereochemically defined dipeptide esters of nucleoside-analogous antiviral agents including acyclovir and ganciclovir are provided. Certain of these stereochemically defined dipeptide esters are found to have unexpectedly enhanced delivery to and uptake by ocular tissues, crossing the blood-ocular barrier more effectively than other stereochemically defined dipeptide esters. For example, (L-Val)-(D-Val)-acyclovir was found to be taken up more effectively into corneal tissue than were underivatized acyclovir, monoesters (L-Val)-acyclovir or (D-Val)-acyclovir, or diester (L-Val)-(L-Val)-acyclovir. | 06-11-2009 |
20100152212 | PREQ1 RIBOSWITCHES AND METHODS AND COMPOSITIONS FOR USE OF AND WITH PREQ1 RIBOSWITCHES - The preQ1 riboswitch is a target for antibiotics and other small molecule therapies. The preQ1riboswitch and portions thereof can be used to regulate the expression or function of RNA molecules and other elements and molecules. The preQ1 riboswitch and portions thereof can be used in a variety of other methods to, for example, identify or detect compounds. Compounds can be used to stimulate, active, inhibit and/or inactivate the preQ1 riboswitch. The preQ1 riboswitch and portions thereof, both alone and in combination with other nucleic acids, can be used in a variety of constructs and RNA molecules and can be encoded by nucleic acids. | 06-17-2010 |
20100249156 | ANTIVIRAL TOPICAL FORMULATIONS IN THE FORM OF A BIO-ADHESIVE GEL - The invention relates to topical formulations in the form of a bioadhesive hydrophilic gel comprising acyclovir as active ingredient, Sodium hyaluronate and an acrylic polymer. Said formulations improve the local administration of acyclovir in the treatment of herpes infections, because they possess good properties of adherence to the mucosa and high resistance to physiological removal mechanisms. | 09-30-2010 |
20110065732 | KIT FOR TOPICAL APPLICATION OF MEDICATION - The application describes a convenient portable kit for the application of topical medications. The kit can be used, for example, as a convenient system for application of cold sore medication. The kit includes a container for a quantity of fluid medication sufficient for several treatments together with a plurality of applicators for said medicine. The applicators are specially designed to apply the medicine accurately and with minimal pain. | 03-17-2011 |
20110275652 | 2,2-BIS-(HYDROXYMETHYL)CYCLOPROPYLIDENEMETHYL-PURINES AND -PYRIMIDINES AS ANTIVIRAL AGENTS - Compounds which are active against viruses have the following formulas: | 11-10-2011 |
20120149720 | VALACYCLOVIR FORMULATIONS - The present invention relates to taste-masked pharmaceutical formulations of valacyclovir. The present invention also relates to process of preparation of valacyclovir suspensions, solutions and dry powder for reconstitution. | 06-14-2012 |
20130005749 | NOVEL FORMULATION AND TREATMENT METHODS - The invention relates to extended release compositions and formulations comprising 6-thioguanine (6-TG), and methods for treating diseases or conditions responsive to 6-TG. | 01-03-2013 |
20130072506 | 6,8-DISUBSTITUTED PURINE COMPOSITIONS - 6,8-Disubstituted purines which can be used in drug and cosmetic compositions and/or applications are provided. These 6,8-disubstituted purines have a wide range of biological activities, including for example anti-inflammatory, anti-senescent, as well as well as other activities which are especially useful in pharmaceutical and cosmetic applications. The 6,8-disubstituted purine compounds and compositions containing such 6,8-disubstituted purines provide growth-regulatory, differentiating, antisenescent and antiaging properties with improved selectivities and efficiencies and lower toxicities than analogues known heretofore. | 03-21-2013 |
20130281470 | Use of (R)-Penciclovir Triphosphate for the Manufacture of a Medicament for the Treatment of Viral Diseases - A method of treatment of: i) HIV-1 infections in mammals, including humans; or ii) HBV infections in mammals, including humans; which method comprises the administration to the human in need of such treatment, an effective amount of the (R)-enantiomer of the triphosphate of a compound of formula (A) or a pharmaceutically acceptable salt thereof; and compounds for use in the method. | 10-24-2013 |
20140213600 | MEDICAMENT FOR TREATING PERIPHERAL NEUROPATHIES - The invention provides a method for treatment of the diseases in a human by identifying the human as one suffering from a herpes simplex virus (HSV), and then administering to the human the compound anti-HSV agent or a pharmaceutically acceptable salt thereof. The diseases include dermatosis and non-dermatosis, wherein the dermatosis include acnes, impetigo, pyoderma gangrenosum, chilblains and psoriasiform, asteatotic dermatitis, ichthyosis, lichen simplex chronicus (Neurodermatitis, Prurigo), seborrhoeic dermatitis, rosacea, perioral dermatitis, epidermal cyst, wound ulcer, discoid lupus erythematosus, vitiligo, Alopecia, diagnostic criteria of some autoimmune diseases such as systemic lupus erythematosus or diabetic skin complications, wherein the non-dermatosis include glomerulonephritis, arthritis, Crohn's disease, ulcerative colitis, myelodysplasia, multiple myeloma, demyelinating disease, Parkison's disease, anemia, cytopenia those among the diagnostic criteria. | 07-31-2014 |
20140296264 | MGMT INHIBITOR COMBINATIONS FOR THE TREATMENT OF NEOPLASTIC DISORDERS - A method of treating a neoplastic disease in a subject includes administering to neoplastic cells of the subject an MGMT inhibitor and at least one of an antimitotic agent or a DNA damaging agent. | 10-02-2014 |
20140315930 | FAST RELEASE SOLID ORAL COMPOSITIONS OF ENTECAVIR - The present invention is directed to fast release pharmaceutical compositions comprising entecavir or its pharmaceutically acceptable salts, process for preparing the same and use of such compositions for the treatment of Hepatitis B virus infection. | 10-23-2014 |